Chemomab Therapeutics Ltd. (CMMB): Operating Income

Annual figures by period end, from SEC filings.

-$112.00M

Year ended 2025-12-31

2024-12-31 Operating Income (USD) 2025-12-31

Period ended	Operating Income	Change YoY	Source filing
2025-12-31	-$112.00M	n/m	2026-03-23, From 2025-01-01
2024-12-31	-$103.00M	n/a	2025-04-04, From 2024-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Income	Change YoY
Chemomab Therapeutics Ltd. (CMMB)	2025-12-31	-$112.00M	n/m
CytoDyn Inc. (CYDY)	2026-05-31	-$38.58M	n/m
Actuate Therapeutics, Inc. (ACTU)	2025-12-31	-$22.50M	n/m
CalciMedica, Inc. (CALC)	2025-12-31	-$23.12M	n/m
Exicure, Inc. (XCUR)	2025-12-31	-$4.23M	n/m
Edesa Biotech, Inc. (EDSA)	2025-09-30	-$7.91M	n/m
Biovie Inc. (BIVI)	2026-06-30	-$22.65M	n/m
NRX Pharmaceuticals, Inc. (NRXP)	2025-12-31	-$16.22M	n/m
Cellectar Biosciences, Inc. (CLRB)	2025-12-31	-$22.98M	n/m

Compare CMMB, CYDY, ACTU, CALC side by side · Screen every company in Pharmaceutical Preparations ↗